
Sign up to save your podcasts
Or


The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.
Learn more about SSRP Institute
Follow for more!
Instagram: @SSRPInstitute | @Redoxmedicalgroup
Youtube: Subscribe Here
By William Seeds, MD4.8
1313 ratings
The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.
Learn more about SSRP Institute
Follow for more!
Instagram: @SSRPInstitute | @Redoxmedicalgroup
Youtube: Subscribe Here

7,205 Listeners

4,986 Listeners

12,147 Listeners

267 Listeners

4,872 Listeners

3,457 Listeners

9,231 Listeners

142 Listeners

129 Listeners

292 Listeners

1,680 Listeners

1,196 Listeners

119 Listeners

3,097 Listeners

79 Listeners